logo-loader
viewSareum Holdings PLC

Sareum reiterates plans to focus on cancer and autoimmune drug programmes

Ahead of the company’s annual meeting, chairman Dr Stephen Parker, said that in SDC-1802, the company has discovered a “potent, orally-available, small molecule contributor to the immune-oncology field, which could prove advantageous over the biological approaches that currently dominate”

Sareum Holdings PLC -

Sareum Holdings PLC has reiterated its plans to focus on the development of its TYK2/JAK1 programmes: SDC-1801, for autoimmune diseases, and SDC-1802, targeting cancer.

Ahead of the company’s annual meeting, chairman Dr Stephen Parker, said that in SDC-1802, the company has discovered a “potent, orally-available, small molecule contributor to the immune-oncology field, which could prove advantageous over the biological approaches that currently dominate”.

Subject to successfully securing the appropriate financial backing, human trials of the drug candidate are scheduled to begin late next year.

At the end of the last financial year, the company had £920,000 in the bank and it raised £780,000 in July.

Parker said: “The board is actively monitoring the working capital position and has taken steps to maximise the runway, constantly ensuring that the two TYK2/JAK1 compounds take priority in resource allocation.”

Plans announced earlier in the year partner Sierra Oncology to ‘on-licence’ a Sareum-developed cancer drug called SRA737 have delayed an estimated US$5mln of milestone payments due to Sareum.

“The board and management team are evaluating our options and making plans accordingly,” investors were told.

Quick facts: Sareum Holdings PLC

Price: 0.885 GBX

AIM:SAR
Market: AIM
Market Cap: £28.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

2 days, 18 hours ago

2 min read